No Data
Express News | Andrew Ratz, Ph.d., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Press Release: Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Wedbush Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $157
Wedbush Lifts Price Target on Neurocrine Biosciences to $157 From $154, Keeps Outperform Rating
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $154
RBC Capital Keeps Their Hold Rating on Neurocrine (NBIX)
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50
Srav Reddy : You missed VSTM and